Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Clinical trial NCT06869785 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06869785
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis (RMS)

Start date: 2025-03-13
Primary completion: 2026-01-28
Enrollment: 196

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.